At the American College of Rheumatology Annual Meeting, which took place in San Francisco, California, USA, from 6 to 11 November 2015, Helen Lachmann, MA, MB BChir, MD, FRCP, from the Royal Free London NHS Foundation Trust, London, UK discusses the results of a trial which analysed the use of canakinumab to treat tumour necrosis factor receptor-associated periodic syndrome (TRAPS), and how they relate to her own experiences in the UK.
Canakinumab in the treatment of tumour necrosis factor receptor-associated periodic syndrome (TRAPS)
19th April 2016
Oncology
Please rate the quality of this content
We are sorry that this content was not interesting for you!
Let us improve this content!
Tell us how we can improve this content?